MedTrace Logo

The Relapses in Childhood Acute Lymphoplastic Leukemia Excluding L3

NCT05969600 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 521

Last updated 2023-08-01

No results posted yet for this study

Summary

Background: acute lymphoblastic leukemia is the most common childhood cancer and relapse is the main reason for treatment failure in childhood acute lymphoblastic leukemia.

The aim of this study: is to assess the relapse of childhood acute lymphoblastic leukemia in pediatric patients treated in the Child's Central Teaching Hospital/ Baghdad.

Methods: A retrospective study that reviewed 521 children with newly diagnosed ALL for children below 15 years during the period from 1st of January 2013 to 1st of March 2020 in the hemato-oncology ward in the Child's Central Teaching Hospital in Baghdad, with a total duration of follow-up for two years post last starting treatment (till 1st of March 2022 ).

Conditions

  • Leukemia, Acute

Sponsors & Collaborators

  • Central Teaching Hospital of Peadiatrics, Baghdad

    lead OTHER

Eligibility

Min Age
2 Months
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-01
Primary Completion
2020-03-01
Completion
2022-03-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05969600 on ClinicalTrials.gov